1279 related articles for article (PubMed ID: 16636176)
1. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
2. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
[TBL] [Abstract][Full Text] [Related]
4. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
[TBL] [Abstract][Full Text] [Related]
5. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
6. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
8. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
[TBL] [Abstract][Full Text] [Related]
9. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.
Heymans S; Schroen B; Vermeersch P; Milting H; Gao F; Kassner A; Gillijns H; Herijgers P; Flameng W; Carmeliet P; Van de Werf F; Pinto YM; Janssens S
Circulation; 2005 Aug; 112(8):1136-44. PubMed ID: 16103240
[TBL] [Abstract][Full Text] [Related]
10. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
Webb CS; Bonnema DD; Ahmed SH; Leonardi AH; McClure CD; Clark LL; Stroud RE; Corn WC; Finklea L; Zile MR; Spinale FG
Circulation; 2006 Sep; 114(10):1020-7. PubMed ID: 16923753
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
Hoheisel G; Sack U; Hui DS; Huse K; Chan KS; Chan KK; Hartwig K; Schuster E; Scholz GH; Schauer J
Tuberculosis (Edinb); 2001; 81(3):203-9. PubMed ID: 11466032
[TBL] [Abstract][Full Text] [Related]
12. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
13. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
15. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
16. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension.
Hirono O; Fatema K; Nitobe J; Takeishi Y; Kaneko K; Shiga R; Kubota I
J Cardiol; 2002 Apr; 39(4):195-204. PubMed ID: 11977767
[TBL] [Abstract][Full Text] [Related]
18. Cardiac remodeling and failure From molecules to man (Part II).
Fedak PW; Verma S; Weisel RD; Li RK
Cardiovasc Pathol; 2005; 14(2):49-60. PubMed ID: 15780796
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy.
Tozzi R; Palladini G; Fallarini S; Nano R; Gatti C; Presotto C; Schiavone A; Micheletti R; Ferrari P; Fogari R; Perlini S
Am J Hypertens; 2007 Jun; 20(6):663-9. PubMed ID: 17531925
[TBL] [Abstract][Full Text] [Related]
20. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
